Table 1.
Descriptives
| Variables |
Hypo Na (N = 388) |
Normal Na (N = 300) | p‐value | Having symptoms | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Yes (N = 313) |
No (N = 375) |
P‐value | |||||||||
| Sex, N (%) | Male | 188 | (48.5) | 152 | (50.7) | .56 | 150 | (47.9) | 190 | (50.7) | .49 |
|
Treatment outcome, a N (%) (missing 17) |
failure | 157/375 | (41.9) | 67/296 | (22.6) | 125/303 | (41.3) | 99/368 | (26.9) | ||
| response | 76/375 | (20.3) | 106/296 | (35.8) | 65/303 | (21.5) | 117/368 | (31.8) | |||
| moderate | 142/375 | (37.9) | 123/296 | (41.6) | <.001 | 113/303 | (37.3) | 152/368 | (41.3) | <.001 | |
|
Concomitant ASMs b (missing 22) |
Monotherapy | 74/371 | (19.9) | 99/295 | (33.6) | <.001 | 58/302 | (19.2) | 115/364 | (31.6) | <.001 |
| Mean age (SD), years | 47.3 | (15.0) | 40.9 | (17.0) | <.001 | 45.8 | (16.2) | 43.4 | (16.1) | .06 | |
| Mean sodium level (SD), mEq/L | 129.6 | (3.9) | 139.7 | (6.0) | 131.0 | (5.9) | 136.47 | (4.9) | <.001 | ||
|
Mean drug level (SD), mg/L (CBZ, missing 34; OXC, missing 23) |
CBZ | 8.3 | (2.2) | 7.6 | (2.1) | .001 | 8.2 | (2.3) | 7.8 | (2.1) | .07 |
| OXC | 22.0 | (7.0) | 20.1 | (6.9) | .12 | 21.8 | (6.4) | 20.8 | (7.6) | .38 | |
Abbreviations: ASM, anti‐seizure medication; CBZ, carbamazepine; Hypo Na, hyponatremia; OXC, oxcarbazepine.
a
Treatment outcome is a categorical variable with groups failure (<50% seizure frequency reduction), response (seizure freedom >1 year), and moderate (seizure frequency reduction ≥50%, not seizure‐free).
b
Concomitant ASMs = dichotomous variable (mono vs polytherapy)